SCHEMBL634036

SCHEMBL634036

Cc1c(C)c2c(c(C)c1OCCC(=O)O)CCC(C)(CCCC(C)CCCC(C)C)O2

nearest known ligand 0.82

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 4/20 0.82
GSTO1 P78417 2/20 0.78
PTPN1 P18031 1/20 0.78
MEN1 O00255 2/20 0.72
KMT2A Q03164 2/20 0.72
PDE4A P27815 1/20 0.72
PDE3A Q14432 1/20 0.72
LMNA P02545 3/20 0.65
TTPA P49638 3/20 0.65
MAPT P10636 2/20 0.65
GSTP1 P09211 1/20 0.65
USP2 O75604 1/20 0.65
THRB P10828 1/20 0.65
CYP2C9 P11712 1/20 0.65
CYP2C19 P33261 1/20 0.65
NR1I2 O75469 3/20 0.60
ALOX5 P09917 1/20 0.60
PGR P06401 1/20 0.51
AKT1 P31749 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13657154 1.00 PSEN1 (0.82) PSEN1GSTO1PTPN1MEN1KMT2A
SCHEMBL2142325 1.00 PSEN1 (0.82) PSEN1GSTO1PTPN1MEN1KMT2A
SCHEMBL3096752 0.96 PSEN1 (0.75) PSEN1GSTO1PTPN1MEN1KMT2A
SCHEMBL31330188 0.95 PSEN1 (0.81) PSEN1GSTO1PTPN1MEN1KMT2A
SCHEMBL627980 0.95 PSEN1 (0.81) PSEN1GSTO1PTPN1MEN1KMT2A
SCHEMBL2141324 0.95 PSEN1 (0.81) PSEN1GSTO1PTPN1MEN1KMT2A
SCHEMBL25278931 0.94 PSEN1 (0.77) PSEN1GSTO1PTPN1MEN1KMT2A
SCHEMBL25233309 0.94 PSEN1 (0.77) PSEN1GSTO1PTPN1MEN1KMT2A
SCHEMBL13657155 0.94 PSEN1 (0.79) PSEN1GSTO1PTPN1MEN1KMT2A
SCHEMBL627940 0.94 PSEN1 (0.79) PSEN1GSTO1PTPN1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100273871-A1 ANTICANCER TOCOPHERYL SUCCINATE DERIVATIVES THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2010-10-28 US claimed
EP-2418948-B1 ANTIADHESION AGENTS UNIV OHIO STATE RES FOUND (US) 2013-09-04 EP disclosed
US-8461362-B2 Protein phosphatase 2A-activating agents THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2013-06-11 US disclosed
US-8362071-B2 Antiadhesion agents THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2013-01-29 US disclosed
US-8362071-B2 Antiadhesion agents THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2013-01-29 US disclosed
US-8362071-B2 Antiadhesion agents THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2013-01-29 US disclosed
EP-2418948-A1 ANTIADHESION AGENTS The Ohio State University Research Foundation (US) 2012-02-22 EP disclosed
WO-2010121111-A9 ANTIADHESION AGENTS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2011-12-22 WO disclosed
US-20100273871-A1 ANTICANCER TOCOPHERYL SUCCINATE DERIVATIVES THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2010-10-28 US disclosed
US-20100273871-A1 ANTICANCER TOCOPHERYL SUCCINATE DERIVATIVES THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2010-10-28 US disclosed
US-20100267820-A1 ANTIADHESION AGENTS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2010-10-21 US disclosed
US-20100267820-A1 ANTIADHESION AGENTS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2010-10-21 US disclosed
US-20100267820-A1 ANTIADHESION AGENTS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2010-10-21 US disclosed
US-20100267673-A1 PROTEIN PHOSPHATASE 2A-ACTIVATING AGENTS THE OHIO SATE UNIVERSITY RESEARCH FOUNDATION (US) 2010-10-21 US disclosed
WO-2010121111-A1 ANTIADHESION AGENTS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2010-10-21 WO disclosed
EP-1986635-A4 ANTICANCER AGENTS UNIV OHIO STATE RES FOUND (US) 2009-04-22 EP disclosed
EP-1986635-A2 ANTICANCER AGENTS THE OHIO STATE RESEARCH FOUNDATION (US) 2008-11-05 EP disclosed
US-20080009545-A1 Anticancer agents THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2008-01-10 US disclosed
WO-2007098139-A2 ANTICANCER AGENTS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273871-A1 ANTICANCER TOCOPHERYL SUCCINATE DERIVATIVES SDHA, SDHB, SUCNR1 PSEN1 1751/4885GSTO1 191/4885PTPN1 4113/4885
US-20080009545-A1 Anticancer agents SUCNR1, CPS1, HIF1AN PSEN1 3626/4885GSTO1 1338/4885PTPN1 2349/4885
US-20100267673-A1 PROTEIN PHOSPHATASE 2A-ACTIVATING AGENTS PPP2CA, PPP2R2A, PPP2R1A PSEN1 1965/4885GSTO1 251/4885PTPN1 386/4885
US-20100267820-A1 ANTIADHESION AGENTS SELE, EPCAM, SELP PSEN1 3830/4885GSTO1 80/4885PTPN1 4843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.